Botulinum toxin drugs: brief history and outlook

被引:35
作者
Dressler, D. [1 ]
机构
[1] Hannover Med Sch, Dept Neurol, Movement Disorder Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Botulinum toxin; Therapeutic use; History; Future perspectives; Global market; INJECTION;
D O I
10.1007/s00702-015-1478-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The global botulinum toxin (BT) market is currently undergoing rapid changes: this may be the time to review the history and the future of BT drug development. Since the early 1990s Botox (R) and Dysport (R) dominated the international BT market. Later, Myobloc (R)/NeuroBloc (R), a liquid BT type B drug, came out, but failed. Xeomin (R) is the latest major BT drug. It features removal of complexing proteins and improved neurotoxin purity. Several new BT drugs are coming out of Korea, China and Russia. Scientific challenges for BT drug development include modification of BT's duration of action, its transdermal transport and the design of BT hybrid drugs for specific target tissues. The increased competition will change the global BT market fundamentally and a re-organisation according to large indication groups, such as therapeutic and cosmetic applications, might occur.
引用
收藏
页码:277 / 279
页数:3
相关论文
共 50 条
[41]   Botulinum toxin in the management of facial paralysis [J].
Cabin, Jonathan A. ;
Massry, Guy G. ;
Azizzadeh, Babak .
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2015, 23 (04) :272-280
[42]   Botulinum toxin to treat pelvic pain [J].
Zhang, Yingchun ;
Smith, Christopher P. .
TOXICON, 2018, 147 :129-133
[43]   Botulinum Toxin to Minimize Facial Scarring [J].
Jablonka, Eric M. ;
Sherris, David A. ;
Gassner, Holger G. .
FACIAL PLASTIC SURGERY, 2012, 28 (05) :525-535
[44]   Is myasthenia gravis a contraindication for botulinum toxin? [J].
Ma, Qian ;
Ran, Hao ;
Ou, Changyi ;
Liu, Xiaoxi ;
Lu, Yaru ;
Huang, Huan ;
Yang, Wenhao ;
Yu, Lu ;
Chen, Pei ;
Huang, Xin ;
Qiu, Li ;
Lin, Zhongqiang ;
Huang, Zhidong ;
Liu, Weibin .
JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 95 :44-47
[45]   Botulinum toxin therapy in rehabilitative neurology [J].
Dressler, D ;
Argyrakis, A ;
Schonle, PW ;
Wochnik, G ;
Ruther, E .
NERVENARZT, 1996, 67 (08) :686-694
[46]   Botulinum Toxin: From Drug to Poison [J].
Dressler, D. ;
Saberi, F. A. .
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2009, 77 :S49-S54
[47]   Is botulinum toxin a cause or a cure for headaches? [J].
Mullaaziz, Didem ;
Kaptanoglu, Asli .
JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (02) :595-599
[48]   Botulinum toxin: A lift for chronic migraines [J].
Sanassi, Lorraine A. .
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2016, 29 (06)
[49]   New analgesic: Focus on botulinum toxin [J].
Lackovic, Zdravko .
TOXICON, 2020, 179 :1-7
[50]   Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs [J].
Simpson, LL .
BIOCHIMIE, 2000, 82 (9-10) :943-953